These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
249 related items for PubMed ID: 17118782
1. Could BEACOPP be the new standard for the treatment of advanced Hodgkin's lymphoma (HL)? Diehl V, Behringer K. Cancer Invest; 2006 Nov; 24(7):713-7. PubMed ID: 17118782 [Abstract] [Full Text] [Related]
4. Will BEACOPP be the standard for high risk Hodgkin lymphoma patients in advanced stages? Diehl V, Fuchs M, GHSG. Transfus Apher Sci; 2007 Aug; 37(1):37-41. PubMed ID: 17714996 [Abstract] [Full Text] [Related]
6. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group. Behringer K, Breuer K, Reineke T, May M, Nogova L, Klimm B, Schmitz T, Wildt L, Diehl V, Engert A, German Hodgkin's Lymphoma Study Group. J Clin Oncol; 2005 Oct 20; 23(30):7555-64. PubMed ID: 16234521 [Abstract] [Full Text] [Related]
9. [New therapeutic strategies for Hodgkin lymphoma in cooperation of radiation oncology and medical oncology]. Eich HT, Müller RP, Ansén S, Josting A, Engert A, Hansemann K, Pfistner B, Wolf J, Willich N, Diehl V. Rontgenpraxis; 2003 Oct 20; 55(3):114-24. PubMed ID: 15119314 [Abstract] [Full Text] [Related]
11. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. Diehl V, Franklin J, Pfreundschuh M, Lathan B, Paulus U, Hasenclever D, Tesch H, Herrmann R, Dörken B, Müller-Hermelink HK, Dühmke E, Loeffler M, German Hodgkin's Lymphoma Study Group. N Engl J Med; 2003 Jun 12; 348(24):2386-95. PubMed ID: 12802024 [Abstract] [Full Text] [Related]
12. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. Viviani S, Zinzani PL, Rambaldi A, Brusamolino E, Levis A, Bonfante V, Vitolo U, Pulsoni A, Liberati AM, Specchia G, Valagussa P, Rossi A, Zaja F, Pogliani EM, Pregno P, Gotti M, Gallamini A, Rota Scalabrini D, Bonadonna G, Gianni AM, Michelangelo Foundation, Gruppo Italiano di Terapie Innovative nei Linfomi, Intergruppo Italiano Linfomi. N Engl J Med; 2011 Jul 21; 365(3):203-12. PubMed ID: 21774708 [Abstract] [Full Text] [Related]
13. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group. Josting A, Wiedenmann S, Franklin J, May M, Sieber M, Wolf J, Engert A, Diehl V, German Hodgkin's Lymphoma Study Group. J Clin Oncol; 2003 Sep 15; 21(18):3440-6. PubMed ID: 12668650 [Abstract] [Full Text] [Related]
14. Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma. Skoetz N, Will A, Monsef I, Brillant C, Engert A, von Tresckow B. Cochrane Database Syst Rev; 2017 May 25; 5(5):CD007941. PubMed ID: 28541603 [Abstract] [Full Text] [Related]
15. Current clinical trials for the treatment of advanced-stage Hodgkin's disease: BEACOPP. Franklin J, Diehl V. Ann Oncol; 2002 May 25; 13 Suppl 1():98-101. PubMed ID: 12078913 [Abstract] [Full Text] [Related]
16. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Engert A, Haverkamp H, Kobe C, Markova J, Renner C, Ho A, Zijlstra J, Král Z, Fuchs M, Hallek M, Kanz L, Döhner H, Dörken B, Engel N, Topp M, Klutmann S, Amthauer H, Bockisch A, Kluge R, Kratochwil C, Schober O, Greil R, Andreesen R, Kneba M, Pfreundschuh M, Stein H, Eich HT, Müller RP, Dietlein M, Borchmann P, Diehl V, German Hodgkin Study Group, Swiss Group for Clinical Cancer Research, Arbeitsgemeinschaft Medikamentöse Tumortherapie. Lancet; 2012 May 12; 379(9828):1791-9. PubMed ID: 22480758 [Abstract] [Full Text] [Related]
17. Intensified treatment of patients with early stage, unfavourable Hodgkin lymphoma: long-term follow-up of a randomised, international phase 3 trial of the German Hodgkin Study Group (GHSG HD14). Gillessen S, Plütschow A, Fuchs M, Markova J, Greil R, Topp MS, Meissner J, Zijlstra JM, Eichenauer DA, Bröckelmann PJ, Diehl V, Borchmann P, Engert A, von Tresckow B. Lancet Haematol; 2021 Apr 12; 8(4):e278-e288. PubMed ID: 33770483 [Abstract] [Full Text] [Related]
18. Ten years' experience with four cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, procarbazine (BEACOPP)-escalated followed by four cycles of baseline-dose BEACOPP in patients with advanced stage Hodgkin lymphoma: a single-center, retrospective study. Belada D, Štěpánková P, Sýkorová A, Žák P, Smolej L. Leuk Lymphoma; 2015 Jul 12; 56(7):2013-8. PubMed ID: 25330440 [Abstract] [Full Text] [Related]
19. Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial. Engert A, Josting A, Haverkamp H, Villalobos M, Lohri A, Sökler M, Zijlstra J, Sturm I, Topp MS, Rank A, Zenz T, Vogelhuber M, Nogova L, Borchmann P, Fuchs M, Flechtner HH, Diehl V. J Clin Oncol; 2010 May 01; 28(13):2239-45. PubMed ID: 20368566 [Abstract] [Full Text] [Related]
20. Salvage radiotherapy in patients with relapsed and refractory Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group. Josting A, Nogová L, Franklin J, Glossmann JP, Eich HT, Sieber M, Schober T, Boettcher HD, Schulz U, Müller RP, Diehl V, Engert A. J Clin Oncol; 2005 Mar 01; 23(7):1522-9. PubMed ID: 15632410 [Abstract] [Full Text] [Related] Page: [Next] [New Search]